Free tool
FAERS Monitor: Aqneursa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219132 or its brand name (Aqneursa, Levacetylleucine). Reports on generic versions are filed under their own applications.
Reports
251
Serious
63
25% of reports
Hospitalization
26
Death reported
14
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use140
- fall11
- product use in unapproved indication11
- seizure11
- vomiting9
- dysphagia8
- pneumonia8
- gait disturbance7
- pneumonia aspiration7
- decreased appetite6
- diarrhoea6
- product use issue6
- death5
- drug ineffective5
- insomnia5
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2023 | 1 |
| 2024 | 7 |
| 2025 | 151 |
| 2026 | 91 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,908 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pneumonia aspirationSignal | 7 | 23.5 | 11.3 | 129 |
| off label useSignal | 140 | 13.4 | 12.0 | 1,663 |
| seizureSignal | 11 | 8.0 | 4.5 | 61 |
| dysphagiaSignal | 8 | 7.1 | 3.6 | 36 |
| product use in unapproved indicationSignal | 11 | 3.7 | 2.1 | 19 |
| gait disturbanceSignal | 7 | 3.1 | 1.5 | 8 |
| fallSignal | 11 | 2.8 | 1.6 | 11 |
| product use issueSignal | 6 | 2.7 | 1.2 | 5 |
| decreased appetite | 6 | 2.2 | 1.0 | 3 |
| pneumonia | 8 | 2.1 | 1.0 | 3 |
| vomiting | 9 | 1.6 | 0.8 | 2 |
| insomnia | 5 | 1.6 | 0.7 | 1 |
| diarrhoea | 6 | 0.8 | 0.4 | 0 |
| death | 5 | 0.5 | 0.2 | 2 |
| drug ineffective | 5 | 0.3 | 0.1 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.